After months of dealing with COVID-19 and overcoming several challenges of implementation, London and Aachen were able to start there clinical investigations in April. Previously, Utrecht, Stockholm and Leuven were able to start so this means that all five partners are participating in the Nightingale Phase 3 clinical investigation with the device of Checkpoint Cardio!
In the clinical investigations, each site will involve at least 25 patients at high risk of deterioration. Each site was given the flexibility to select the most suitable patient population at their location. The objectives at each site are to investigate the performance and usability of the system. The results and experience gained from the investigations will allow for identification of remaining challenges and opportunities for wireless, remote monitoring of high-risk patients.